Law360, New York (April 04, 2011, 3:07 PM ET) -- Takeda Pharmaceutical Co. Ltd. launched a patent infringement suit Friday in New York over Dr. Reddy’s Laboratories Ltd.’s efforts to manufacture a generic version of acid reflux treatment Dexilant.
The Indian generic-drug maker and its U.S. subsidiary Dr. Reddy’s Laboratories Inc. have infringed U.S. Patent Numbers 6,664,276 and 7,790,755 through the submission of an abbreviated new drug application seeking approval to market their own version of Dexilant, Takeda contends in a complaint filed in the U.S. District Court for the Southern District of New York....
Takeda Targets Dr. Reddy's Over Generic Dexilant
To view the full article, take a free trial now.
